Viking Global Investors

Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies to Tackle the Underlying Causes of Severely Debilitating Diseases

Retrieved on: 
Wednesday, April 3, 2024
Hereditary hemorrhagic telangiectasia, Telangiectasia, Biotechnology, Blood, Disease, Atlas, Patient, Lung, Stroke, Viking Global Investors, Death, Artery, Chiari malformation, Rupture, Intraparenchymal hemorrhage, Heart failure, Lightspeed Venture Partners, Therapy, TGF, Antibody, Bleeding, Heart, Pharmacology, Unified school district, HHT, PAH, Atlas Venture, Pulmonary hypertension, Pharmaceutical industry

CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company pioneering a new approach to discovering and developing agonist antibodies, launched today with $128 million in financing. The Series A was co-led by BVF Partners and Atlas Venture, with participation from Lightspeed Venture Partners, RA Capital Management, Frazier Life Sciences, Viking Global Investors, Velosity Capital, and Checkpoint Capital. Diagonal was co-founded by Chief Executive Officer, Alex Lugovskoy, Ph.D., and Atlas and previously seeded by Atlas, Lightspeed Venture Partners, and Velosity Capital. The financing will support further advancement of the company’s proprietary DIAGONAL platform and pipeline of novel therapeutics to value-creating milestones, including its lead program for the treatment of hereditary hemorrhagic telangiectasia (HHT), a severely debilitating bleeding disorder with limited therapeutic options, through clinical proof-of-concept. Diagonal's agonist antibody activates a receptor complex in the TGF-β superfamily genetically impaired in HHT patients. In preclinical models of HHT, Diagonal's agonist antibodies prevent and reverse the formation of pathological vascular malformations.

Key Points: 
  • Diagonal was co-founded by Alex Lugovskoy, Ph.D., and Atlas and previously seeded by Atlas, Lightspeed Venture Partners, and Velosity Capital.
  • CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company pioneering a new approach to discovering and developing agonist antibodies, launched today with $128 million in financing.
  • Diagonal was co-founded by Chief Executive Officer, Alex Lugovskoy, Ph.D., and Atlas and previously seeded by Atlas, Lightspeed Venture Partners, and Velosity Capital.
  • In preclinical models of HHT, Diagonal's agonist antibodies prevent and reverse the formation of pathological vascular malformations.

Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock

Retrieved on: 
Monday, March 18, 2024
Committee, Partnership, SAN, Viking Global Investors, Doctor of Philosophy, Standard BioTools, Standard, Series, Security (finance)

SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has exchanged all outstanding shares of its Series B Convertible Preferred Stock (the “Series B Preferred”) for shares of common stock pursuant to an agreement with stockholders affiliated with Viking Global Investors (“Viking”) and Casdin Capital (“Casdin").

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has exchanged all outstanding shares of its Series B Convertible Preferred Stock (the “Series B Preferred”) for shares of common stock pursuant to an agreement with stockholders affiliated with Viking Global Investors (“Viking”) and Casdin Capital (“Casdin").
  • Thomas Carey, Chairman of the Standard BioTools Board of Directors, said, “We are pleased to reach this agreement with Viking and Casdin.
  • This exchange price resulted in the issuance of approximately 17.8 million additional shares of common stock, as compared to the shares of common stock issuable under the Series B Preferred’s stated $3.40 per share conversion price.
  • As a result, the Company now has approximately 382.5 million shares of common stock outstanding.

APi Group Announces Pricing of Upsized Secondary Public Offering of Common Stock

Retrieved on: 
Friday, March 1, 2024
Other Manufacturing, Technology, Construction & Property, Security, HVAC, Utilities, Building Systems, Manufacturing, Energy, Other Construction & Property, Attention, API, J.P. Morgan & Co., CJS, Prospectus, Viking Global Investors, UBS, Sale, Form, Blackstone Inc., BofA Securities, Security (finance), Barclays, Form S-3, Citigroup, Jefferies

APi Group Corporation (NYSE: APG) (“APi” or the “Company”) announced the upsize and pricing of the previously announced underwritten registered public offering of 10,569,106 shares of common stock of the Company commenced by certain funds affiliated with Blackstone Inc. (the “Blackstone Selling Stockholders”) and Viking Global Investors LP (the “Viking Selling Stockholders”), collectively, the “Selling Stockholders,” at a public offering price of $34.25 per share.

Key Points: 
  • APi Group Corporation (NYSE: APG) (“APi” or the “Company”) announced the upsize and pricing of the previously announced underwritten registered public offering of 10,569,106 shares of common stock of the Company commenced by certain funds affiliated with Blackstone Inc. (the “Blackstone Selling Stockholders”) and Viking Global Investors LP (the “Viking Selling Stockholders”), collectively, the “Selling Stockholders,” at a public offering price of $34.25 per share.
  • The Selling Stockholders received the offered shares upon conversion of then-existing 5.5% Series B Perpetual Convertible Preferred Stock (the “Series B Preferred Shares”).
  • In connection with the offering, the Selling Stockholders granted the underwriters a 30-day option to purchase up to 1,585,365 additional shares of common stock held by the Selling Stockholders.
  • APi is not selling any shares of common stock and will not receive any proceeds from the sale of the shares of common stock in the offering.

APi Group Announces Launch of Secondary Public Offering of Common Stock

Retrieved on: 
Wednesday, February 28, 2024
Other Manufacturing, Technology, Construction & Property, Security, HVAC, Utilities, Building Systems, Manufacturing, Energy, Other Construction & Property, Attention, API, Prospectus, Viking Global Investors, UBS, Sale, Form, Blackstone Inc., Security (finance), Citigroup, Partner

In connection with the offering, the Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to 1,219,510 additional shares of common stock held by the Selling Stockholders.

Key Points: 
  • In connection with the offering, the Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to 1,219,510 additional shares of common stock held by the Selling Stockholders.
  • APi is not selling any shares of common stock and will not receive any proceeds from the sale of the shares of common stock in the offering.
  • UBS Investment Bank and Citigroup are acting as joint bookrunning managers for the offering and Blackstone Securities Partners L.P. is acting as co-manager.
  • The offering of the shares of common stock is being made only by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Mainstay Medical Announces US$125 Million Equity Financing Transaction

Retrieved on: 
Monday, February 26, 2024
Health, Medical Devices, Neurology, Health Technology, Physical Therapy, Other Health, Biotechnology, Research, Viking Global Investors, E-GMS, Insurance, Pharmaceutical industry

Mainstay Medical Holdings plc today announced an equity financing in which it will receive gross proceeds of US$125 million.

Key Points: 
  • Mainstay Medical Holdings plc today announced an equity financing in which it will receive gross proceeds of US$125 million.
  • Mainstay intends to use the funds to support the company’s continued commercial growth of ReActiv8® Restorative Neurostimulation in the U.S., Europe and Australia, additional post-market clinical studies and research, and general operations.
  • The financing was co-led by new investors Gilde Healthcare and Viking Global Investors.
  • Key existing investors who participated in the financing include Ally Bridge Group, Sofinnova Partners (Crossover Fund), Fountain Healthcare Partners, and Perceptive Advisors.

Areteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic Asthma

Retrieved on: 
Tuesday, February 13, 2024
Biotechnology, Pharmaceutical, Health, Maverick Capital, Sanofi, Asthma, Therapy, ARCH Venture Partners, GV, Viking Global Investors, Pharmaceutical industry

Areteia Therapeutics, Inc. (“Areteia”) today announced $75 million in additional Series A financing to support expansion of the current Phase III development program of dexpramipexole in eosinophilic asthma, bringing total Series A funding to $425 million.

Key Points: 
  • Areteia Therapeutics, Inc. (“Areteia”) today announced $75 million in additional Series A financing to support expansion of the current Phase III development program of dexpramipexole in eosinophilic asthma, bringing total Series A funding to $425 million.
  • “We are delighted that leading biotech investors like Viking Global Investors and Marshall Wace have joined the syndicate.
  • Their investment in Areteia further deepens our already strong capitalization position,” said Jorge Bartolome, President and Chief Executive Officer of Areteia.
  • “We are pleased with the strong demand in this investment expansion round as our phase III program in eosinophilic asthma continues to make excellent progress.”

ORIC Pharmaceuticals Announces $125 Million Private Placement Financing

Retrieved on: 
Monday, January 22, 2024
Research, SAN, New Enterprise Associates, Prospectus, Sale, Nex Entertainment, NEA, Viking Global Investors, Security (finance)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that it has agreed to sell approximately 12.5 million shares of its common stock to a select group of institutional and accredited healthcare specialist investors in a private placement, at a price per share of $10.00, representing a premium of approximately 10% to ORIC’s 5-day trailing average price. The financing is expected to close on January 23, 2024, subject to customary closing conditions. ORIC anticipates the gross proceeds from the private placement to be approximately $125 million, before deducting any offering related expenses.

Key Points: 
  • The financing is expected to close on January 23, 2024, subject to customary closing conditions.
  • ORIC anticipates the gross proceeds from the private placement to be approximately $125 million, before deducting any offering related expenses.
  • The financing includes participation from new and existing institutional investors, including Viking Global Investors, Commodore Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, NEA, and Nextech1.
  • ORIC has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock issued in this private placement.

Lightmatter Accelerates Growth and Expands Photonic Chip Deployments With $155M in New Funding; Now Valued at $1.2B

Retrieved on: 
Tuesday, December 19, 2023
Software, Internet, Hardware, Artificial Intelligence, Engineering, Technology, Semiconductor, Manufacturing, Cloud, Dialog Semiconductor, Sambanova, Viking Global Investors, GV (company), Architecture, AI, HPC, IP, General counsel, Growth, Silicon, GV, General partnership, Communication, Senior

With this round, Lightmatter has raised over $420 million to date and is now valued at over $1.2B.

Key Points: 
  • With this round, Lightmatter has raised over $420 million to date and is now valued at over $1.2B.
  • This new financing allows the company to expedite growth to meet the increasing demand for high-performance computing (HPC) from AI innovators.
  • Lightmatter plans to expand its world-class team and office footprint, while accelerating its ability to provide customers increased performance on the most advanced AI workloads.
  • He brings over 20 years of semiconductor industry experience to Lightmatter and was most recently Senior Vice President and General Counsel at Dialog Semiconductor.

Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company’s Proposed Merger with Standard BioTools

Retrieved on: 
Tuesday, December 12, 2023
Professional Services, Finance, Disclosure, Indian psychology, WGS, NYSE, Viking Global Investors, Shareholder, Acquisition, Thermo Fisher Scientific, Security (finance), Therapy, PIPE, Combination, Proteomics, CFO, Investment, Depression, GREEN, Standard, Serum, Illumina, Inc., TMO, Weather, Special, Partnership, Mergers and acquisitions, Growth, Puerto Madryn, Environment, Holding company, Fine chemical, Cryptocurrency, Retail, Bank, Plasma, Series, SomaLogic, Illumina

Additionally, Madryn announced it has filed a preliminary proxy statement with the Securities and Exchange Commission (“SEC”) in order to solicit proxies in opposition to the Merger.

Key Points: 
  • Additionally, Madryn announced it has filed a preliminary proxy statement with the Securities and Exchange Commission (“SEC”) in order to solicit proxies in opposition to the Merger.
  • That is why we intend to vote AGAINST the Merger at the upcoming Special Meeting on January 4, 2024.
  • Additionally, we have taken steps to soon be in a position to actively solicit your votes AGAINST the Merger.
  • In the meantime, we urge you to reach out to SomaLogic to express your views on the Merger.

DermBiont Announces First Close of $35.2 Million in a Series B Financing to Advance First-in-Class Targeted Topical Dermatological Therapeutics

Retrieved on: 
Tuesday, October 24, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Olive, FDA, Viking Global Investors, Food, Hyperpigmentation, Therapy, PKC, Skin, DPN, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Laser, Melasma, Physician, Recurrence, Venture round, Civilization, Dermatology, Safety, SKS, SK, Series, Patient, AKT, Dermatosis papulosa nigra, Pharmaceutical industry, Dietary supplement

DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of dermatological indications, today announced a $35.2 million Series B financing, including a $27.1 million Series B first close and $8.1 million in converting outstanding notes.

Key Points: 
  • DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of dermatological indications, today announced a $35.2 million Series B financing, including a $27.1 million Series B first close and $8.1 million in converting outstanding notes.
  • The Series B was led by new institutional investor, Double Point Ventures, and includes continued support from Viking Global Investors, Civilization Ventures, Olive Tree Capital, and others.
  • These products prioritize the patient experience by addressing the root cause of both diseases with excellent efficacy, safety, and tolerability.
  • Phase 2b open label clinical trial in 10 subjects with DPN (Dermatosis Papulosa Nigra) treated with SM-020 gel 1% twice daily for 28 days.